Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion type Assertion NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_head.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion description "[Switching from the current standard of care vemurafenib therapy to the double BRAF/MEK inhibition in BRAF mutant melanoma patients results in rapid disappearance of established proliferative skin disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_provenance.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion evidence source_evidence_literature NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_provenance.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion SIO_000772 25185693 NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_provenance.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion wasDerivedFrom befree-2016 NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_provenance.
- NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_assertion wasGeneratedBy ECO_0000203 NP1216528.RARKrtqgjq4PgmaansuUidFlzNQ7xSEjYuoZGbZHPqZ1E130_provenance.